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ABSTRACT  
Project I: 
    Currently, chemotherapy is the only treatment for metastatic prostate cancer. 
However, due to toxicity and resistance, the currently available chemotherapeutic 
drugs are not good enough to control this disease. To find a novel and effective 
method to treat this disease, we studied the effect of interferons (IFNs) and 
double-stranded RNA (dsRNA) on the apoptosis of prostate cancer cells. 
Interestingly, pretreatment of PC3 cells, a human prostate adenocarcinoma cell 
line, with IFNs significantly sensitized these cells to dsRNA induced apoptosis, 
and cell apoptosis was confirmed by a variety of assays such as Annexin V, 
TUNEL, DNA fragmentation and the activity of caspase 3.  In comparison with 
IFN-α or  treatment, IFN-γ treatment remarkably augmented dsRNA-induced 
apoptosis in PC3 cells.  By using mutant cell lines, we demonstrated that IFN-
signaling is necessary for these effects. Silence of dsRNA-dependent protein 
kinase R (PKR) and RNAse L by siRNA did not have any significant impact on 
vi 
 
this event, suggesting that neither RNase L nor PKR is involved. Further 
investigation of the apoptotic pathway revealed that Bak, a pro-apoptotic member 
of the Bcl-2 family, is up-regulated by IFN-γ and dsRNA. Our findings may lead to 
the design of novel therapeutic strategies for prostate cancer. 
 
Project II:  
     Transmembrane and coiled-coil domains 1 (TMCO1) is a membrane-
associated protein with unknown function. Recently, a homozygous frame shift 
mutation, c.139_140delAG, has been identified in the TMCO1 gene in patients 
with TMCO1 defect syndrome (TDS). TDS is characterized by distinctive 
craniofacial dysmorphism, skeletal anomalies, and mental retardation. In order to 
study the biological function of this gene, human TMCO1 was expressed in both 
bacteria and mammalian cells. The recombinant TMCO1 expressed in bacteria 
was purified in order to prepare an antibody, and subcellular localization revealed 
that TMCO1 may be expressed in the mitochondria of cells. Further study 
showed that the lymphocytes isolated from peripheral blood of patients with TDS 
grew significantly faster than those from healthy individuals, suggesting that 
TMCO1 may be involved in the regulation of cell proliferation.  In addition, we 
have generated a TMCO1 knock down cell line, which will be used to further 
study the molecular basis of TDS. 
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CHAPTER I 
INTRODUCTION 
 
 
Project I: Human prostate cancer cell apoptosis induced by interferon-γ 
(IFN- γ) and double-stranded RNA (dsRNA)  
 
1.1.1 Prostate cancer: epidemiology and treatment 
     The prostate is a small gland situated just below the bladder and surrounding 
the urethra (Figure 1.1.1). Its size and shape are similar to a walnut [American 
cancer society, 2009]. The function of a prostate is to produce the seminal fluid 
through which sperm is transported. Usually prostate cancer arises if the prostate 
cells fail to grow in an organized and controlled manner, which eventually leads 
to the formation of a tumor. 
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Figure 1.1.1 Prostate cancer [American cancer society, 2009] 
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     In developed countries, prostate cancer is the second most frequently 
diagnosed cancer in men. Although prostate specific antigen (PSA) screening 
and early detection have been undertaken to reduce the mortality [Baade, et al., 
2004], prostate cancer is still the second leading cause of cancer death in men, 
affecting about one in six men in the United States [Damber, et al., 2008]. The 
American Cancer Society estimates that there were about 192,280 new cases of 
prostate cancer in the United States in 2009 and that about 27,360 men died of 
the disease during that year. 
      The treatment of prostate cancer depends on the cancerous stages of 
patients. Localized disease is curable. For aged patients, especially with slowly 
growing tumors, watchful waiting may be suggested. In the case of young 
patients and fast growing tumors, the most common treatments are radical 
prostatectomy and transurethral resection of the prostate [Chowdhury, et al., 
2007; Strief, et al., 2007]. Radiation therapy, a treatment with radiation to kill and 
shrink cancer cells, is applied as the first treatment for low-grade cancer that has 
not spread outside the prostate gland or to local tissues. Cryosurgery, a 
technique using metal probes to freeze prostate cancer cells, can also be used 
for the treatment of prostate cancer that has not spread. For men who are 
diagnosed with a metastatic disease, there is only one choice: the androgen-
ablation therapy, also called hormonal therapy.  This treatment decreases the 
level of androgen, causing the prostate tumor to shrink or to grow more slowly. 
Unfortunately, hormonal therapy is effective for an average of only 2 years and 
most patients eventually become refractory to hormonal therapy. Hormone-
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refractory prostate cancer (HRPC) is a common condition that causes 
considerable morbidity and mortality.  To date, cytotoxic chemotherapy is 
thought to be the best way to control this situation. Recent studies have shown 
that docetaxel chemotherapy can achieve a remarkable improvement on the 
survival of HRPC patients. Thus docetaxel treatment has become the first-line 
chemotherapy treatment for HRPC and has been approved for use in the United 
States and Europe. However, lack of a response and development of resistance 
to docetaxel in a considerable number of patients limit its applications in prostate 
cancer therapy, requiring that most patients with HRPC undergo as much as 
third-line treatments [Chang and Kibel, 2008]. Therefore, development and 
discovery of new drugs capable of prolonging survival have become an urgent 
clinical need.  
 
1.1.2 Overview of the IFN system and their biological functions  
     IFNs are a family of cytokines expressed in all eukaryotic cells as an early 
response to multiple stimuli, such as viral infection, dsRNA, and immune 
inducers [Stark, et al., 1998]. There are two major classes of IFNs: type I and 
type II. Type I IFNs consist of several subtypes, mainly IFN-α and IFN-, and are 
induced in most cell types by viruses and dsRNA; whereas type II IFN is induced 
potentially in T lymphocytes and natural killer cells in response to immune and 
inflammatory stimulation [Samuel, et al., 2001]. Most recently, a new type of IFN-
like protein was identified and classified as Type III IFN or IFN-λ [Kotenko, et al., 
2003].  
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     Despite the differences in their amino acid sequences, all three types of IFNs 
display similar biological responses through inducing the expression of a series 
of IFN-stimulated genes (ISGs). The well-established IFN signaling pathways 
involve tyrosine phosphorylation, the activation of the Janus tyrosine kinases 
(JAKs), and the signal transducers and activators of transcription (STATs). 
Although the JAK/STAT signaling pathway is used by all three types of IFNs, the 
components and transducing mode in the pathways are distinctive (Figure 1.1.2).  
After binding with type I IFN, dimerization of type I IFN receptor subunits, 
IFNAR1 and IFNAR2, leads to the initiation of a tyrosine phosphorylation 
cascade (JAK1 and Tyk2), resulting in the association of STAT1 and STAT2. The 
phosphorylated STAT1/STAT2 heterodimer is associated with the DNA-binding 
protein p48 (in cytoplasm) to form a heterotrimer complex (ISGF3) which 
translocates into the nucleus, binding to the IFN-stimulated regulatory element 
(ISRE) of type I IFN responsive genes to initiate transcription. In type II IFN 
signaling, the activated type II receptor subunits IFNGR1 and IFNGR2 are 
associated with and activate JAK1 and JAK2, which subsequently phosphorylate 
STAT1. The phosphorylated STAT1 forms a homodimer, which translocates to  
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Figure 1.1.2 IFN signaling pathway [Kotenko, et al., 2003] 
 
7 
 
the nucleus where it binds to the gamma-activated sequence (GAS) of IFN-γ-
inducible genes to stimulate transcription.  The type III IFN uses the same 
JAK/STAT pathway as type I IFN, but through different receptors. In recent years, 
studies have revealed that IFNs are able to activate other signaling pathways, 
such as the mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-
kinase (PI3-K) pathways [Platanias and Fish, 1999]. However, the biological 
significance of this cross-talk between IFN signaling and other signaling 
pathways remains to be fully understood. 
 
1.1.3 IFNs and apoptosis 
     Apoptosis is a naturally occurring process by which a cell is directed to the 
programmed death. Apoptosis serves to eliminate undesired or superfluous cells 
in a targeted manner and plays an important role in tissue development, 
homeostasis, and differentiation. When cells go through apoptotic characteristics, 
changes take place in cell morphology, condensation of the chromatin, 
degradation of DNA, and cell shrinkage. Other commonly used biomarkers 
include cleavage of poly (ADP-ribose) polymerase (PARP), release of 
cytochrome C from mitochondria, and an increase of caspase activities. 
Additionally, apoptosis is involved in regulating the functions of the immune 
system and eliminating altered cells. Thus, abnormalities in the regulation of cell 
apoptosis can lead to various diseases, including cancer, autoimmunity, and 
degenerative disorders [Pommier, et al., 2001; Schulze-Bergkamen and 
Krammer, 2004; Liu et al., 2004; Tatton, et al., 2003; Roth, 2001]. 
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     Type I and Type II IFNs are able to effectively induce apoptosis in a wide 
range of malignant cell types, such as herpes-associated lymphomas, acute 
promyelocytic leukemia (APL), non-small-cell lung cancer, non-melanoma skin 
cancer and glioma [Barber, 2003].  It is believed that IFNs induce cell apoptosis 
through activating the death receptor cascade (Figure 1.1.3) [Chawla-Sarkar, et 
al., 2003]. The induction of TRAIL, and/or Fas/FasL, in response to IFNs leads to 
recruitment and activation of FADD. FADD activation in turn activates caspase-8, 
initiating the activation of the caspase cascade. On the other hand, IFNs also 
induce caspase-4 and caspase-8. Activated caspase-8 cleaves Bid, a 
proapoptotic member of Bcl-2 family, resulting in disruption of mitochondrial 
potential and the release of cytochrome C from the mitochondria into the 
cytoplasm where it acts as a cofactor to stimulate the complex of Apaf1 with 
caspase-9, subsequently activating proscaspase-3. A variety of ISGs, including 
the members of the IFN regulatory factor (IRF) family, dsRNA dependent protein 
kinase (PKR), 2-5A dependent RNase L (RNase L), TNF-related apoptosis-
inducing ligand (TRAIL), promyelocytic leukemia gene (PML), and the death-
associated proteins (DAPs), exert their tumor suppressing functions through 
inducing apoptosis in tumor cells [Chawla-Sarkar, et al., 2003]. Interestingly, the 
involvements of different ISGs in IFN-induced apoptosis depend on cell types. 
For example, TRAIL and XIAP associated factor 1(XAF1) are believed to  
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Figure 1.1.3 Mechanism of IFN-induced apoptosis [Zimmermann, 2001] 
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contribute to IFN-induced apoptosis in melanoma cells, whereas an induction of 
regulators of IFN-induced death (RIDs) is necessary in IFN-induced ovarian 
carcinoma cell apoptosis. The survival benefit may invoke a cancer cell to 
selectively inhibit one or more of the apoptotic ISGs, or acquire defects in IFN-
signal transduction components.  
 
1.1.4 Clinical application of IFNs in cancer treatment 
     The applications of IFNs in the treatment of cancer have been studied 
extensively. To a certain extent, success has been achieved in the treatment of 
several malignant hematological diseases and solid tumors by IFNs [Friedman, 
2008]. Treatment with IFN-, the first IFN used in the treatment of cancer, results 
in significant clinical responses and prolongs survival in patients with hairy cell 
leukemia, chronic myelogenous leukemia, renal cell carcinoma, ovarian cancer, 
hepatocellular carcinoma, and melanoma [Walter, et al., 1998; Wadler and 
Schwartz, 1997; Borden and Parkinson, 1998; Baker, et al., 2002; Borden, et al., 
2002, Borden, et al., 2007 and Hastie, et al., 2008]. Furthermore, clinical trials 
have revealed that IFN- 
tumors including renal cell carcinoma, Kaposi’s sarcoma, and melanoma. Pre-
clinical studies have shown that IFNs are able to inhibit the growth of prostate 
cancer cells. For example, IFN-β increases the expression of the androgen 
receptor, improving adhesion potential of androgen-insensitive prostate cancer 
cells [Angelucci, 2007]. Forced expression of human IFN-β in human prostate 
cancer cells can significantly inhibit the prostatic growth which has been 
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correlated with down regulation of angiogenic molecules [Lee, 2006].  
Adenovirus-mediated delivery of the IFN-γ gene can inhibit the growth of prostate 
cancer cells in vitro and xenografts in vivo [Zhao, et al., 2007]. IFNs have also 
been used in clinical trials for prostate cancer patients [Van Haelst-Pisani, et al. 
1992; Bulbul, et al. 1986]. However, the role of IFNs in the treatment of prostate 
cancer is under-studied, particularly in clinical applications. The limited 
application is due to high toxicity accompanied by limited beneficial effect 
[Kuratsukuri, et al., 2000]. To solve these problems, IFNs have been used in 
combination with other cytotoxic agents for the treatment of prostate cancer in 
recent years. For example, IFN- is combined with paclitaxel or 13-cis-retinoic 
acid in a phase I clinical trial to treat prostate cancer [Thalasila, et al., 2003]; a 
phase II study indicates that IFN-γ as an adjuvant enhances antitumor effects in 
131I-labeled high affinity CC49 monoclonal antibody therapy in patients with 
metastatic prostate cancer [Meredith, et al., 1999]; the combination 
chemotherapy of 5-fluorouracil and a low dose of IFN- in patients with HRPC 
proves feasible with acceptable toxicity [Shinohara, et al., 1998]. Thus, a 
combination of IFN with other cytotoxic agents may be a novel approach for 
prostate cancer therapy. 
 
1.1.5 DsRNA and cell apoptosis 
      The synthetic dsRNA, Polyinosinic:polycytidylic acid ( Poly I:C), is a toll-like 
receptor 3 (TLR 3) ligand and a potent inducer of type I IFN.  Poly I:C is active 
against a number of transplanted tumors, such as melanoma and leukemia [Bart 
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and Kopf, 1969; Zeleznick and Bhuyan, 1969]. It can also inhibit the growth of a 
variety of human tumor cells in culture, for example colon carcinoma cells and 
bladder carcinoma cells [Lin, et al., 1982; Hubbel, et al., 1984].  Poly I: C induces 
cell apoptosis through multiple pathways such as TLR3, NF-kappaB, interferon 
regulatory factors 3 (IRF3), and the IFN stimulated pathway [Chin, et al., 2010; 
Huang, et al., 2006]. Although the therapeutic efficacy and toxicity of dsRNA in 
the treatment of cancer patients have been evaluated in the past years, its 
striking side-effects have greatly blocked its clinical applications because the 
therapeutic responses are observed only at high doses [Friboulet, et al., 2010]. 
Furthermore, several laboratories have reported that if dsRNA is delivered by 
cationic liposome to cancer cells, it can inhibit the growth of many cancer cells 
even at a low concentration, suggesting a possible clinical application of dsRNA 
[Okamoto, et al. 1998].  It has been observed that 25µg/mL poly I:C can inhibit 
LNcap cell (prostate cancer cell) proliferation through the IFN-independent 
pathway involving protein kinase C activation; however, 25ug/mL poly I:C only 
has slight inhibition effect on the PC3 cell proliferation [Paone, et al., 2008]. 
Furthermore, it has been reported that human IFN and dsRNA can synergistically 
inhibit the growth of some human cancer cells, but studies about the mechanism 
are largely lacking [Chapekar and Glazer, 1985; Chapekar and Glazer, 1986]. 
Also, there are no reported studies on checking the effect of IFNs and dsRNA on 
prostate cancer cell apoptosis. 
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1.1.6 Our hypothesis 
     The effect of IFNs on prostate cancer has been studied for decades, but the 
limited application of IFNs on the treatment of prostate cancer is due to the 
cytotoxicity and lack of efficacy in prostate cancer patients. To solve these 
problems, IFNs have recently been used in combination with other cytotoxic 
agents for the treatment of prostate cancer. On the other hand, the antitumor 
function of the adjuvant molecule poly I:C has been studied extensively; however, 
the significantly inhibiting effect of poly I:C on human malignant cells has been 
performed with a very high concentration of 100µg/m. Recently, the combination 
of low dose of poly I:C with other factors such as the IAP (inhibitor of apoptotic 
protein) inhibitor RMT 5265 can produce a synergistic effect on apoptosis 
induction and/or inhibition of clonogenic growth [Friboulet, et al., 2010]. Here, we 
hypothesis that a low dose of IFNs combined with a low dose of dsRNA may 
augment the inhibiting effect on the growth of prostate cancer cells. 
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Project II: studies on the biological roles of TMCO1 
 
1.2.1 Human chromosome 1 and its related diseases 
     Chromosome 1 is the largest of the human chromosomes, spanning about 
260 million base pairs and containing 8% of the human genome [Gregory, et al., 
2006]. There are about 3,000 genes on chromosome 1 and due to this great 
number of genes, there are also a large number of diseases associated with 
chromosome 1. Over 350 human diseases have been linked to the disruption in 
the sequence of chromosome 1 including cancers, neurological, developmental 
disorders, distinctive facial features, birth defects, cardiovascular disease, and 
other medical problems [Ohya, et al., 2006; Povey and Parrington, 1986]. A few 
examples include: Parkinson’s disease, familial adenomatous polyposis, 
Alzheimer’s disease, porphyria cutanea tarda, Chediak–Higashi syndrome, 
Diamond–Blackfan syndrome, factor V Leiden thrombophilia, hereditary 
antithrombin III deficiency, Gaucher disease, type 2 hemochromatosis, etc.  
[Caramazza, et al., 2010]. Changes to chromosome 1 may include a missing 
segment of the short (p)  or long arm (q) of the chromosome in each cell (partial 
monosomy 1p or 1q), an extra segment of the short or long arm of the 
chromosome, or a circular structure called ring chromosome 1 
[http://ghr.nlm.nih.gov/chromosome=1]. For instance, the nonrandom duplication 
of the long arm material of chromosome 1, which tends to occur at a relatively 
late stage of cancer, may contribute to the progression of all forms of cancer 
[Atkin, 1986]. Impressively, chromosome 1 plays an important role in the 
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regulation of the development and growth of humans, which can be seen in 
several developmental disorders. One disorder, known as1p36 deletion 
syndrome, is a disease characterized by typical craniofacial dysmorphism, 
developmental delay, and mental retardation.  In individuals with1p36 deletion 
syndrome, the genetic deletion on the outermost band of the short arm of 
chromosome 1 (1p36 chromosome region) occurs, which includes de novo 
terminal 1p36 deletion, interstitial deletion, complex chromosome 
rearrangements, 1p36 deletion with a 1p36 duplication, or a derivative 
chromosome 1 [Battaglia, et al., 2008].  The clinical features of GLUT1 deficiency 
syndrome are mental and developmental delay, hypoglycorrhachia. This 
syndrome is caused by various de novo mutations in the facilitated human 
glucose transporter 1 gene (1p34.2) [Aktas, et al., 2010]. Chromosome 1q 
syndrome is another developmental disorder related to Chromosome 1. The 
interstitial deletion of chromosome 1q ( q23-q31) causes pre- and postnatal 
growth retardation, severe psychomotor retardation, microbrachycephaly and 
some other clinical syndromes [Schwemmle, et al., 2006]. 
  
1.2.2 Introduction of the human TMCO1 gene 
     The human TMCO1 gene is located on chromosome 1q22-q25.  TMCO1 is a plasma 
membrane-associated protein and belongs to the DUF841 superfamily of several 
eukaryotic proteins with unknown functions based on the predicted amino acid sequence 
[Zhang, et al., 2010]. TMCO1 is also known as HP10122, PCIA3, PNAS-136, RP11-
466F5.7 or TMCC4. An earlier study proved that HP10122, an alias for TMCO1, is  
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Figure 1.2.1 Ideograms of chromosome 1 (http://ghr.nlm.nih.gov 
/chromosome=1) 
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 located in the endoplasmic reticulum and Golgi apparatus in COS7 cells 
( Monkey kidney cell line) by fusing TMCO1 with a green fluorescent protein tag 
[Iwamuro, et al., 1999], whereas another recent study showed the porcine 
TMCO1 localizing in mitochondrion [Zhang, et al.,  2010]. A full-length cDNA 
clone HP10122, isolated from human HT-1080 cDNA library, contains a 5’-
untranslated region of 138bp, an open reading frame of 567bp, and a 3’-
untranslated region of 481bp [Iwamuro, et al., 1999]. The TMCO1 gene consists 
of seven coding exons, and the 564-bp coding region encodes a predicted 
protein of 188 amino acids. Figure 1.2.2 shows the schematic structure of 
TMCO1 protein [Xin, et al., 2010]. One coiled-coil domain (amino acids 32-89) 
and two transmembrane segments (amino acids 10-31 for TM1 and amino acids 
90-109 for TM2) were predicted by SMART sequence analysis. Reversible 
phosphorylations of serine, threonine, and tyrosine residues are critical steps in 
the signal transduction pathways. Previous studies indicate that three 
phosphorylation sites (phosphoserines) involved in the signaling networks across 
the cell cycle are identified [Olsen, et al., 2006; Nousiainen, et al., 2006; Wang, 
et al., 2008; Daub, et al., 2008; Dephoure, et al., 2008; Yachie, et al., 2009]. 
There are two known isoforms of the human TMCO1 protein which are produced 
by alternative splicing.   The expression of TMCO1 transcript is universal in 
different tissues; the EST profile of the NCBI database (UniGene Hs.31498) 
shows that the TMCO1 transcript was found to be expressed in 42 of 45 adult 
tissues examined. Furthermore, mRNA expression of TMCO1 was displayed at 
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Figure 1.2.2 Schematic protein structure of TMCO1 [Xin, et al., 2010] One 
coiled-coil domain (amino acids 32-89) and two transmembrane segments 
(amino acids 10-31 for TM1 and amino acids 90-109 for TM2) were predicted by 
SMART sequence analysis. The red stars indicate three verified phosphoserine 
residues.  
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all developmental stages, including the embryoid body, blastocyst, fetus, neonate, 
infant, juvenile, and adult 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Hs.31498). 
The HP10122 mRNA was detected by Northern blot analysis as a single band of 
1.5kb in various human tissues with different expression levels: highly expressed 
in the thymus, prostate, testis and small intestine and scarce in kidney, placenta, 
lung, and brain [Iwamuro, et al., 1999]; while in swine, the quantitative PCR 
results indicated that the expression of TMCO1 mRNA was higher in the liver, 
heart and kidney, significant in doris, logngissimus, backfat, brain, lymph, lung, 
large intestine, small intestine and lower in stomach and spleen [Zhang, et al.,  
2010].  From the amino acid sequence comparison, it has been known the entire 
sequence is highly conserved  with 100% homology among eight mammalian 
TMCO1 proteins in GenBank [Xin, et al., 2010]; analysis by a SOSUI software 
predicts the secondary structure of the TMCO1 protein as a membrane protein 
with a transmembrane helix [Zhang, et al., 2010].   
 
1.2.3 TMCO1 defect syndrome 
     A unique autosomal recessive condition characterized by distinctive 
craniofacial dysmorphism, skeletal anomalies, and mental retardation was 
described in Old Order Amish of Northeast Ohio. This condition was called 
TMCO1 defect syndrome [Xin, et al., 2010]. The typical craniofacial dysmorphism 
includes highly arched bushy eyebrows, long eyelashes, brachycephaly, 
26 
 
synophrys, low-set ears, microdontism of primary teeth, and generalized gingival 
hyperplasia; whereas, skeletal anomalies are represented by sprengel deformity 
of the scapula, rib abnormities, pes planus, fusion of the spine and pectus 
excavatum (Figure 1.2.3). Depressed deep tendon reflexes, unstable gait, and 
intention tremor were found in some older patients through neurological 
examination.  
     Through genome-wide single nucleoid polymorphysim (SNP) homozygosity 
mapping in affected individuals from a consanguineous pedigree (Figure 1.2.4), a 
single large, shared block of homozygous SNPs was identified on chromosome 
1q23.3-q24.1, and 23 genes were revealed from the examination of the minimal 
shared region. From gene sequencing, homozygous 2-base pair deletion 
(c.139_140delAG) within exon 2 of the TMCO1 gene was identified as the 
pathogenic change in patients with TMCO1 defect syndrome. It is predicted that 
this homozygous frame shift mutation can result in premature truncation of 
translation at amino acid position 47.  
 
1.2.4 Biological function of TMCO1 
     The biological process and function of the TMCO1 gene are still unknown, 
and there are few papers available to indicate the biological function of TMCO1.  
     TMCO1 may be involved in the lipid metabolism, since TMCO1 is down-
regulated in liver and adipose tissues in response to a 3-day fast [Lkhagvadori, et 
al., 2009]. The relationship between TMCO1 and cancers can be found in several 
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Figure 1.2.3 Clinical features of TMCO1 defect syndrome [Xin, et al., 2010]. 
(A-G) Facial characteristics of this syndrome; (H) Brain Magnetic resonance 
imaging (MRI) of a patient with TDS indicating prominence of cerebrospinal fluid 
space around the frontal lobes with extension into the anterior interhemisheric 
fissure; (I) Chest x-ray film of an affected individual showing multiple rib 
anomalies.
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Figure 1.2.4 Partial pedigree chart of the family with TMCO1 defect 
syndrome [ Xin, et al., 2010]. ■, affected males; □, unaffected males; ●, affected 
females; ○, unaffected females; ══, consanguinity.  
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studies: meta-analysis  of microarray data showed that TMCO1 is upregulated in 
breast cancer [Kondrakhin, et al., 2008]; TMCO1 may be a potential 
pharmacogenomic predictor in phase II clinical trials of trastuzumab for breast 
cancer [Pusztai, et al., 2007]; and in  bladder cancer, the previous study indicates 
that lipolysis stimulated lipoprotein receptor (LSR) can be upregulated by P53, 
which may impair bladder cancer cells from gaining invasive properties. 
Affymetrix GeneChips experiment shows that siRNA knockdown of LSR leads to 
the down regulation of TMCO1 expression [Herbsleb, et al., 2008]. BCL6 is a 
BTB/POZ domain transcription repressor that is required for normal germinal 
center development and is expressed by the majority of normal GC B cells and a 
subset of diffuse large B cell lymphomas [Polo, et al., 2007]. The BCL6 targeting 
proteins are enriched in modulators of transcription, chromatin structure, protein 
ubiquitylation, cell cycle, and DNA damage responses. As one of BCL6 targeting 
genes, TMCO1’s biological activities may be found among some of these events. 
Furthermore, TMCO1 is found to be associated with the onset of diabetes and 
renal function in a type II diabetes mouse model. In this study, the TMCO1 
transcript ratios in liver, brain, islets, EDL, soleus muscle, and adipose between 
diabetes-susceptible DBA/2J mice and diabetes-resistant C57BL/6J mice were 
calculated [Dokmanovic-Chouinard, et al., 2008]. TMCO1 may be involved in the 
regulation of renal water excretion through altered Aquaporin-2 (a molecular 
water channel). Altered Aquaporin-2 protein, which is abundant in the renal 
collecting duct, is the main factor responsible for water balance abnormalities 
associated with different clinical states.  TMCO1 is one of Aquaporin-2’s 
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transcriptional regulators and is expressed only in the medullary thick ascending 
limb cells and renal proximal tubule cells in native rats, but not in the renal 
collecting duct [Yu, et al., 2009]. Most recently, other possible functions of 
TMCO1 may be outlined by Musashi 1 study. Musashi1 is a highly conserved 
RNA-binding protein with pivotal functions in stem cell maintenance, nervous 
system development, and tumorigenesis. TMCO1 is one of the Musashi1-
associated mRNAs, which implicates that the TMCO1’s biological function is 
related to at least one of Musashi 1’s functions: 1) cell cycle, cell proliferation, cell 
differentiation, and apoptosis; 2) protein modification (including ubiquitination and 
ubiquitin cycle); and 3) tumor formation [De Sousa Abreu, et al., 2009]. In 
summary, more work needs to be done to dig out the systematic functions of 
TMCO1. 
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CHAPTER II 
HUMAN PROSTATE CANCER CELL APOPTOSIS INDUCED BY 
INTERFERON-γ AND DOUBLE-STRANDED RNA 
 
 
2.1 Abstract 
     Interferons (IFNs) are a family of pleiotropic cytokines responsible for inducing 
innate and adaptive immunities against a wide-range of viruses and other 
microbial pathogens. IFNs also exert antitumor activities due to their anti-
proliferative, immunomodulatory, and proapoptotic functions. In recent years, 
studies have revealed that a combination of IFNs with cytotoxic compounds, 
such as paclitaxel and thalidomide, augments the cytotoxicity for prostate cancer 
cells in an additive manner. Here we report that pretreatment of PC3 cells, a 
human prostate adenocarcinoma cell line, with IFNs sensitized these cells to 
dsRNAs-induced apoptosis. The enhancement effect of IFN treatment was 
dependent on IFN subtypes, particularly IFN-γ.  In comparison with IFN-α or , 
IFN-γ treatment remarkably augmented dsRNA-induced apoptosis in PC3 cells, 
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and by  using mutant cell lines, we demonstrated that IFN-signaling is necessary 
for these effects. The silencing of dsRNA-dependent protein kinase R (PKR) and 
RNase L by siRNA did not have any significant impact on this event, suggesting 
that neither RNase L nor PKR is involved in this event. Further investigation of 
the apoptotic pathway revealed that Bak, a pro-apoptotic member of the Bcl-2 
family, was up-regulated by IFN-γ and dsRNA. Our findings may lead to the 
design of novel therapeutic strategies for prostate cancer. 
 
2.2 Introduction 
     Although prostate specific antigen (PSA) screening and digital rectal 
examination have been used widely for the early detection of prostate cancer, 
which bring a dramatic decrease in the mortality rate from prostate cancer, there 
are still a certain amount of patients who undergo disease progression after 
receiving primary treatment [Strief, et al., 2007; Pienta, 2009; Bantis and Vasiliou, 
2009; Bickers and Aukim-Hastie, 2009; Damber and Aus, 2008]. The choices of 
treatment for patients who are diagnosed with metastatic diseases are limited. 
The first line treatment for men with metastatic advanced prostate cancer is 
androgen ablation therapy using either luteinizing hormone releasing hormone 
(LRHR) agonists or surgical castration. Despite the early efficacy of hormone 
ablation therapy, the success of it is short-lived; almost all cases progress to an 
androgen insensitive state called hormone-refractory prostate cancer (HRPC) 
[Priolo, et al., 2009]. Currently there is no cure for the disease at this stage.  
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     The molecular biological characteristics of prostate cancer have been studied 
intensively, and many small-molecule inhibitors and recombinant humanized 
monoclonal antibodies have been tested in the preclinical setting. Although 
promising results have been achieved, many of them have not yielded clearly 
favorable results.  Cytotoxic chemotherapy was thought to be the best choice in 
this situation, and recent studies have shown that docetaxel, a semi-synthetic 
analog of paclitaxel, can achieve a remarkable improvement on the survival of 
HRPC patients by inducing mitotic catastrophe and caspase-2 and -3-dependent 
apoptosis followed by freezing the entire microtubule network [Mediavilla-Varela, 
et al., 2009; Fabbri, et al., 2008].  Docetaxel has thus become the standard 
treatment for metastatic HRPC; however, lack of a response and development of 
resistance to docetaxel in a considerable number of patients limit its applications 
in prostate cancer therapy. Although the actions of other antitumor drugs in 
hormone-resistant prostate cancer were tested and examined, the efficacy of 
current therapy for hormone-refractory prostate cancer is still unsatisfactory 
[Fabbri, et al., 2010]. Therefore, development and discovery of new drugs 
capable of prolonging survival have become an urgent clinical need.         
     IFNs are a family of cytokines expressed in eukaryotic cells as an early 
response to various stimuli, such as viruses, bacteria, parasites, double-stranded 
RNA, and immune inducers [Stark, et al., 1998]. The use of IFNs in the treatment 
of cancer has been studied extensively, and during the recent decades the 
quantity of survivals and quality of lives for many cancer patients have been 
improved dramatically by IFN treatments [Damasio, et al., 2000]. By reviewing 
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literature, a potent synthetic dsRNA IFN inducer, poly I:C,  was found to be active 
against a number of transplanted tumors which can also inhibit the growth of a 
variety of human tumor cells in culture [Bart and Kopf, 1969; Zeleznick and 
Bhuyan, 1969; Lin, et al., 1982; Hubbel, et al., 1984]. However, there are few 
studies concerning the exact mechanism of how these effects are accomplished, 
and the effect of IFNs and dsRNA on prostate cancer cell apoptosis has not been 
reported.   In the present study, we found that the pretreatment of PC3 cells with 
IFN-γ sensitized these cells to small amounts of dsRNA-induced apoptosis. 
Further, we demonstrated that IFN-signaling is necessary for these effects and 
Bak, a pro-apoptotic member of the Bcl-2 family, was up-regulated by IFN- 
γ/dsRNA. Our findings may be beneficial in the design of novel therapeutic 
strategies for prostate cancer. 
 
2.3 Materials and methods 
         
Reagents and antibodies   
     Poly I:C was from Sigma (St. Louis, MO). IFN α, IFN-β and IFN-γ were from R 
& D Systems (Minneapolis, MN). Antibodies to Bax, Bak, Bim, Caspase 3 and 
PKR were from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Anti--actin 
antibody was purchased from Chemicon (Temecula, CA).  
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Cell culture and treatments     
     PC3 cells,  a human prostate cancer cell line (ATCC, Manassas, VA), were 
grown in RPMI-1640 medium (Media Lab of the Central Cell Service, Cleveland 
Clinic, Cleveland, OH) supplemented with streptomycin (100µg/mL), penicillin 
(100unites/mL)  and 10% cosmic calf serum (Hyclone, Logan, UT) in a humidified 
atmosphere of 5% CO2 at 37 
oC. Cells were grown to 90% confluence and 
incubated with 1000units/mL of IFN α, IFN-β or IFN-γ respectively for 18 h 
followed by transfection with or without 2µg/mL of poly I:C using lipofectomine 
(Invitrogen, Carlsbad, CA).  Culture medium was added at 1 h after transfection. 
The effects of IFNs and dsRNA on the cell growth were also examined on DU145 
cells, another prostate cancer cell line (ATCC, Manassas, VA). 
 
Cell viability assay    
     Three days after treatments, the medium color of the cultured cells was 
recorded and the trypan blue dye exclusion assay was used to count viable cells. 
This assay is based on the principle that live cells possess intact cell membranes 
that exclude certain dyes, such as trypan blue, eosin, or propidium, whereas 
dead cells do not. In this test, a cell suspension is simply mixed with dye and 
then visually examined to determine whether cells take up or exclude dye. Cells 
were visualized under Olympus CKX31 at 100X magnification.  
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 Annexin V assay     
     To determine whether the inhibiting effect of IFN-γ/dsRNA on PC3 cells’ 
growth resulted from apoptosis, an Annexin V assay was performed. 
Phosphatidylserine (PS) is a type of phospholipid (Figure 2.3.1). Under normal 
conditions, PS is situated in the inner leaflet of the cell membrane, but at the 
early stage of apoptosis, PS is translocated to the outer leaflet of the cell 
membrane due to the loss of membrane asymmetry. Anenexin-V conjugated with 
flurochromes has very high affinity to PS, so the amount of cells undergoing early 
stage apoptosis can be quantified by measuring the florescence signals using 
flow cytometry. At the same time, the cells are stained with propidium iodine (PI) 
which is another kind of flurochrome. In the late stage of apoptosis the cell 
membrane is disintegrated, allowing PI to enter the cells and bind to the DNA. 
Thus, the cells undergoing later stage apoptosis can be evaluated by PI signals. 
Shown on the right part of Figure 2.3.1 is a typical Annexin-v assay result. The x-
axis represents the number of cells undergoing early stage apoptosis and the y-
axis represents the amount of cells undergoing later stages of apoptosis. The 
signals in the right upper area indicate the total amount of cells that undergo 
apoptosis.      
     In this study, Annexin V assay was performed using an Annexin V-
FITC/propidium iodine apoptosis detection kit (BD Biosciences, San Jose, CA). 
Briefly, PC3 cells treated as described previously were collected and centrifuged 
at 2,000Xg for 5 min at 4oC. Then cells were washed with ice cold PBS and 
resuspended in 1X binding buffer provided by the manufacturer. FITC Annexin-V  
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Figure 2.3.1 Principle of the Annexin-V assay 
(http://www.biocat.com/bc/img/info_pix/PSAnnexin.gif) Phosphatidylserine 
(PS) is a type of phospholipid. At the early stage of apoptosis, PS is re-
translocated to the outer leaflet from the inner leaflet of the cell membrane and 
bound to Anenexin-V, which is conjugated with flurochromes. Apoptotic cells are 
sorting by the florescence signals using flow cytometry. Propidium iodine (PI), 
which is another type of flurochrome, is able to penetrate the disintegrated cell 
membrane of apoptotic cells to bind to the DNA. Thus, the cells undergoing later 
stage apoptosis can be evaluated by PI staining. 
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N
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(5 µL) and propidium iodide (5 µL) were added to cell suspension containing 
1X105 cells for each assay. After incubation for 15 min in the dark at room 
temperature, 400 µL of 1X binding buffer was added to the cell suspension and 
cells were analyzed by two-color cytometry using a FACScanTM (Becton 
Dickinson, Franklin Lake, NJ).  
 
Determination of DNA fragmentation     
     DNA fragmentation represents a characteristic hallmark of apoptosis and the 
DNA fragmentation assay is another typical method used for evaluating cell 
apoptosis. During apoptosis, endonuclease is activated and subsequently 
degrades the DNA molecules in the region between the nucleosomes so that the 
consequent DNA fragments are essentially multiples of 200-base-pair lengths.   
     In this study, DNA in the IFNs/dsRNA treated cells was isolated using an 
apoptotic DNA ladder kit (Roche, South San Francisco, CA). Briefly, 200 μL of 
cell suspensions in PBS was mixed with 200 μL binding buffer (Roche, South 
San Francisco, CA). After incubation for 10 min at room temperature, 100 μL of 
isopropanol (Mallinckrodt Baker, Phillipsburg, NJ) was added to the samples, 
followed by vortexing. DNA was then purified using glass fibers. DNA samples 
with ethidium bromide staining were separated on 2% agarose gel and visualized 
under UV light. 
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TUNEL assay  
     To further confirm whether IFN-γ combined with dsRNA induces PC3 cell 
apoptosis, we performed a terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) assay. Shown on Figure 2.3.2 is the working principle of a 
TUNEL assay. Basically terminal deoxynucleotidyl transferase (TdT) is used to 
transfer deoxyuridine triphosphates (dUTP) conjugated with a fluorochrome to 
these strand breaks of cleaved DNA and the total amount of strand breaks in the 
cleaved DNA is evaluated with flurochrome, such as FITC, by flow cytometry.   
     The TUNEL assay was performed using an APO-BRDU kit (BD Biosciences, 
San Jose, CA). Briefly, IFNs/dsRNA treated PC3 cells were scraped, collected 
and fixed in 1% paraformaldehyde for 45 min followed by washing with PBS 
twice. Then cells were stored in 70% ethanol at -20oC until staining and analysis. 
DNA fragmentation was examined by incorporating Brdu and staining with a 
FITC-labeled anti-BrdU mAb. The total DNA breaks were determined with FITC 
and the labeled cells were sorted by flow cytometry in a FACS. 
 
Caspase activity assay  
     Caspase 3 belongs to a family of cysteine proteases (caspases) that cleave 
proteins at aspartate residues [Strasser, et al., 2000]. Caspase 3 is the 
executioner of cell death in the cell apoptotic pathway and it is worthwhile to 
examine the activity of caspase 3 to evaluate cell apoptosis.  The activity of 
caspase 3 in the cells treated with IFN-γ and /or dsRNA was examined using 
CaspACETM Assay system (Promega, Madison, WI) as instructed by  
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Figure 2.3.2 Working principle of TUNEL assay 
(http://www.biocompare.com/images/bc/006/ArticleImages/RocheApplied_I
nSituCellDeathDetectionKit_slide030_img.jpg). Terminal deoxynucleotidyl 
transferase (TdT) is used to transfer deoxyuridine triphosphates (dUTP) 
conjugated with a fluorochrome to these strand breaks of cleaved DNA and the 
total amount of strand breaks in the cleaved DNA is evaluated with flurochrome, 
such as FITC, by flow cytometry.   
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 manufacturer. This assay is based on caspase cleavage of chromophore p-
nitroaniline (pNA) substrate linked with the tetrapeptide DEVD. Free pNA 
produces a yellow color that is monitored by spectrophotometer at 405 nm. In 
brief, cells were treated as described above and cytosolic extracts were prepared 
by cell lysis buffer provided by the manufacturer. After centrifugation at 15,000Xg 
for 20 min at 4 oC, cell extract containing 50 µg of proteins were transferred into a 
96-well plate to mix with the CaspACETM assay reagent. After incubation for 4 h 
at 37 oC, caspase activity was determined by absorbance at 405 nm using a 
LD400 AD/LD analysis spectrometer (Beckman Coulter, Brea, CA). 
 
Western blot analysis 
     The expressions of several proteins in the apoptotic pathway were examined 
by western blot analysis. PC3 cells were harvested after being treated with IFNs 
and/or dsRNA. Cytoplasmic extracts were prepared by suspension of cell pellets 
in NP-40 lysis buffer [Zhou, et al., 2005]. After centrifugation in a microcentrifuge 
at 40C for 10 min, the supernatant was removed and stored at –800C. Cellular 
extracts were fractionated on SDS-10% polyacrylamide gels and transferred to 
polyvinylidene difluoride membranes (Millipore, Billerica, MA). The membranes 
were blocked with 5% non-fat milk in PBS containing 0.02% sodium azide and 
0.2% (v/v) Tween 20 and incubated with different primary antibodies overnight at 
4oC. The membranes were then washed with PBS containing 0.2% (v/v) Tween 
20 and incubated with corresponding secondary antibodies conjugated with HRP 
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(Cell Signaling Technology, Boston, MA) for 1 h at room temperature. After 
washing, these proteins were detected by a chemiluminescence method, 
according to the manufacturer’s specification (Amersham, Piscataway, NJ). 
 
Inhibition of the expression of dsRNA-dependent protein kinase R (PKR) in 
PC3 cells by small interference RNA (siRNA)    
     PC3 cells were transfected with a heterogeneous mixture of 21-23 bp PKR 
siRNA (New England Biolab, Ipswich, MA) using the transpass R2 transfection 
reagent (New England Biolab, Ipswich, MA) according to the manufacturer's 
instructions. Briefly, PC3 cells were grown to 50% confluence. PKR siRNA was 
incubated with the transfection reagent in serum-free medium for 20 min at room 
temperature. Subsequently, the mixture was evenly dispersed on the cells that 
had been washed with serum-free medium once. The final concentration of 
siRNAs was 12.5 nM.   After being incubated for 3 h, the complete culture 
medium was added to the cells. At 30 h after transfection the cells were treated 
with IFNs and dsRNA as described previously. The apoptotic effects of these 
treatments on the PKR siRNA transfected PC3 cells were analyzed. Meanwhile, 
part of the transfected cells were lysed and western blotting analysis was 
performed to determine the expression of PKR in PC3 cells. 
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Inhibition of the expression of RNase L in PC3 cells by small interference 
RNA (siRNA)    
     A pool of 3 target-specific 20-25 nt RNase L siRNA designed to knock down 
the RNase L gene expression was purchased from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA). PC3 cells were transfected with RNase L siRNA to knock 
down the expression of RNase L in PC3 cells using the Lipofectamine 2000 
transfection reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instruction. Briefly, before transfection, PC3 cells were cultured with antibiotic-
free medium in 60-mm plates overnight and the cells were ready for transfection 
when the cell confluence was around 50%. Ten μL of lipofectamine 2000 was 
added to 300 μL of serum free medium. After being incubated for 5 min at room 
temperature, another 300 μL serum free medium containing 8.3 μL of RNase L 
siRNAs was added to this mixture and incubated for 20 min at room temperature. 
Then the mixture was dispersed evenly to cells. The final concentration of RNAse 
L siRNA was 26 nM. After 4 h, the medium was replaced with complete culture 
medium. At 30 h after transfection, part of the RNAse L siRNA transfected cells 
were collected and pelleted for western blot assay to examine whether the 
expression of RNase L was knocked down and part of the RNAse L siRNA 
transfected cells were treated with IFNs and/or dsRNA as indicated previously. 
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2.4 Results 
 
IFN-γ and dsRNA synergistically decrease PC3 cells viability 
     The cytotoxicity of IFNs has limited its clinical application in the treatment of 
cancers; thus the combinations of IFNs with other cytotoxic agents have recently 
been the new direction for the use of IFNs in cancer treatments. To determine 
the direct effect of IFNs and dsRNA on prostate cancer cells, we treated the PC3 
cells with IFNs and poly I:C. Three days after treatment, the medium color of the 
cells treated with IFN-γ/dsRNA remained pink while medium color of cells treated 
in other ways became yellow (Figure 2.4.1). When cells grow well, the medium 
color will change from pink to yellow due to a change in pH as a result of cell 
waste products; therefore the pink medium in the IFN-γ/dsRNA treated well 
indicated that most cells in this well were dead. Cell viability was analyzed by 
trypan blue exclusion assay; all treated cells exhibited a decrease in their viability, 
but IFN-γ/dsRNA showed a notably stronger ability to suppress PC3 cell growth 
when compared with other types of treatment as shown in Figure 2.4.2. Similar 
results were visualized under Olympus CKX31 at 100X magnification (Figure 
2.4.3). To rule out the bias caused by prostate cancer cell lines, we conducted 
the same experiment on DU145 cells, another prostate carcinoma cell line, and 
similar results were obtained. Most of the IFN-γ/dsRNA treated DU145 cells died, 
while the cells treated in other ways showed normal morphology (Figure 2.4.4). 
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Figure 2.4.1 IFN-γ and dsRNA synergistically decrease PC3 cell viability. 
PC3 cells were treated with 1,000 units/mL of IFN ,  or  overnight, and then 
transfected with or without 2 µg/mL of dsRNA using the lipofectomine reagent. 
The picture was taken on day 3 of the post treatment.  
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Figure 2.4.2 Growth of PC3 cells are inhibited significantly by the IFN-
γ/dsRNA treatment. PC3 cells were treated with 1,000 units/mL of IFN ,  or  
overnight, and then transfected with or without 2 µg/mL of dsRNA using 
lipofectomine. After 48 h, the cells’ viability was analyzed by a trypan blue 
exclusion assay. 1, Control; 2, dsRNA alone; 3, IFN-α; 4, IFN-; 5, IFN-γ; 6, IFN-
α/dsRNA; 7, IFN-/dsRNA; 8. IFN-γ/dsRNA  
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Figure 2.4.3 Morphology of PC3 cells treated with IFN-γ/dsRNA PC3 cells 
were treated with 1,000 units/mL of IFN ,  or  overnight, and then transfected 
with or without 2 µg/mL of dsRNA using lipofectomine. After 3 days, cells were 
visualized under Olympus CKX31 at 100 x magnification.  
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Figure 2.4.4 IFN-γ and dsRNA synergistically inhibit the growth of DU145 
cells. DU145 cells were treated with 1,000 units/mL of IFN ,  or  overnight, 
and then transfected with or without 2 µg/mL of dsRNA using lipofectomine. After 
3 days, cells were visualized under Olympus CKX31 at 100 x magnification.  
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 IFN-γ/dsRNA induce apoptosis in PC3 cells 
     To determine whether the decreased PC3 cell viability was actually a result of 
IFN-γ/dsRNA-induced apoptosis, the translocation of membrane phospholipids 
phosphatidylserine (PS) from the inner to the outer leaflet of the plasma 
membrane was examined as an early event of cell apoptosis. Annexin V is a 35-
36kD Ca2+ dependent, phospholipids-binding protein that has a high affinity for  
PS. Therefore, FITC-conjugated Annexin V is commonly used to identify 
apoptotic cells at an early stage. The Annexin-FITC staining showed that 21.4% 
of PC3 cells were positively labeled with Annexin V after being treated with IFN-
γ/dsRNA, while 4.45% of cells were labled when cells were treated with dsRNA 
only and in IFN-α/dsRNA- and IFN-β/dsRNA-treated wells there were 6.58% and 
6.31% of cells labeled respectively. These results indicated that the combination 
of IFN-γ and dsRNA is a potent inducer of PC3 cell apoptosis (Figure 2.4.5). To 
further confirm that IFN-γ combined with dsRNA can induce PC3 cell apoptosis, 
we performed a TUNEL assay. In TUNEL assay, terminal deoxynucleotidyl 
transferase (TdT) is used to transfer Br-dUTP to the strand breaks of cleaved 
DNA. The total amount of strand breaks in the cleaved DNA was evaluated with 
Anti-Brdu antibody conjugated with FITC. As shown on Figure 2.4.6, the 
combination of IFN-γ and dsRNA induced 4 times more cells undergoing 
apoptosis than IFN-γ- or dsRNA-treatment did. We next evaluated apoptosis by 
DNA fragmentation assay. During apoptosis, endonuclease is activated and cuts 
the DNA molecules in the region between the nucleosomes and then the 
consequent DNA fragments are essentially multiples of 200-base-pair lengths. In 
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this experiment, only the IFNγ/dsRNA treated lane showed DNA fragments, 
suggesting that only IFNγ/dsRNA induced PC3 cell apoptosis (Figure 2.4.7). 
 
IFN-γ/dsRNA activate caspase 3 
     To further characterize the IFNγ/dsRNA induced apoptosis in prostate cancer 
cells, we determined the activity of caspase 3 in IFN-γ and/or dsRNA treated 
PC3 cells. The activity of caspase 3 in the cells treated with IFN-γ and/or dsRNA 
was examined by CaspACETM Assay system (Promega, Madison, WI). IFN-
γ/dsRNA induced the activity of caspase 3 in PC3 cells by 2.8-fold while IFN- γ or 
dsRNA increased the caspase 3 activity by 1.1- and 1.7-fold respectively (see 
figure 2.4.8).  
 
IFN-γ/dsRNA enhance the expression of Bak 
     Apparently, IFN-γ combined with dsRNA was able to effectively induce PC3 
cell apoptosis; the next question is what the molecular mechanism is by which 
IFN-γ /dsRNA activate the apoptotic pathway. In mammalian cells, there are two 
major apoptotic pathways, termed “extrinsic” and “intrinsic” [Elmore, 2007]. The 
extrinsic pathway, also termed as the Death Receptor Pathway, is activated by 
the binding of a “death” ligand to its receptor. Subsequently the adapter proteins 
FADD and caspase 8 are recruited to the intracellular portion of the receptor, 
resulting in the activation of caspase 8 and caspase 3--the executioner of cell 
apoptosis. Cellular stress initiates the intrinsic apoptotic pathway, also termed as 
the Mitochondrial Pathway, and involves the upregulation of BH3-only proteins 
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such as Bim, PUMA, and Bad. These proteins inhibit the activity of the anti-
apoptotic Bcl-2 proteins, resulting in Bax dimerization and translocation to the 
mitochondria, subsequently triggering the release of cytochrome C. Then 
Cytochrome C combined with APAF-1 and caspase 9 forms apoptosome and 
further promotes caspase 3 cleavage and activation, leading to apoptosis (see 
Figure 2.4.9).  To test how IFN-γ and dsRNA affect the apoptotic signaling 
pathways, several members of this pathway were examined using western blot 
analysis. Bak, a pro-apoptotic member of the Bcl-2 family, was upregulated by 
IFN-γ/dsRNA (see Figure 2.4.10). The full length of caspase 3 was significantly 
decreased in IFN-γ/dsRNA treated cells, suggesting that caspase 3 was cleaved 
and activated to trigger cell apoptosis. However, there was no significant 
difference in the expression of Bax, Bim and caspase 8 among different 
treatments. 
 
JAK/SATA pathway is involved in IFN-γ/dsRNA induced PC3 cell apoptosis 
     It is believed that IFNs execute most of their functions through IFN’s Jak-stat 
signaling pathway [Borden, et al., 2007]. To examine the role of Jak-stat pathway 
in the IFN-γ/dsRNA-induced prostate cancer cell apoptosis, we determined two 
mutant cell lines: U3A and LNcap cells. The U3A cell is a stat1 null human 
fibrosarcoma cell line and the 2FTGH cell is its parental cell line, while the LNcap 
cell is a prostate cancer cell line with Jak1 deficiency. In these experiments, U3A 
and LNcap cells were treated as previously described and the cell viability was  
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Figure 2.4.5 Determination of PC3 cell apoptosis by Annexin-V analysis 
PC3 cells were pretreated with 1,000 units/mL of IFN ,  or  overnight and then 
treated with 2µg/mL of dsRNA and subjected to Aneexin-V assay by flow 
cytometry after 20 h incubation.  
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Figure 2.4.6 Determination of PC3 cell apoptosis by TUNEL assay PC3 cells 
were pretreated with 1,000 units/mL of IFN ,  or  overnight and treated with 2 
µg/mL dsRNA. After 20 h, the cells were scraped, collected and fixed in 1% 
paraformaldehyde for 45 min, followed by washing with PBS twice. Then cells 
were stored in 70% ethanol at -20oC until staining and analysis. DNA 
fragmentation was examined by incorporating Brdu and staining with a FITC-
labeled anti-BrdU mAb. The total DNA breaks were determined with FITC and 
the labeled cells were sorted by flow cytometry.  
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Figure 2.4.7 IFN-γ and dsRNA induce DNA fragmentation in PC3 cells DNA 
in the IFNs/dsRNA treated cells was isolated using an apoptotic DNA ladder kit 
(Roche, South San Francisco, CA), separated by agarose gel, stained with 
ethidium bromide and visualized under UV light. 
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Figure 2.4.8 Caspase 3 activity assay The activity of caspase 3 in PC3 cells 
treated with IFN-γ and /or dsRNA for 10 h was examined using CaspACETM 
Assay system. Briefly, the treated cells were lysed and the cell extract containing 
50 µg of proteins was transferred into a 96-well plate to mix with the CaspACETM 
assay reagent. After incubation for 4 h at 37 oC, caspase activity was determined 
by absorbance at 405 nm using a LD400 AD/LD analysis spectrometer.  
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Figure 2.4.9 A scheme of major apoptotic pathways in mammalian cells 
(www.healthcare.uiowa.edu/research/sfrbm/papers/.../Tome-Apoptosis.ppt)  
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Figure 2.4.10 Effect of IFN-γ and dsRNA on the expression of apoptotic 
proteins PC3 cells were harvested after being treated with IFNs and/or dsRNA 
for 20 h. Cellular extracts were fractionated on 10% SDS-PAGE and transferred 
to PVDF membrane. The membranes were blocked with 5% no fat milk in PBS 
containing 0.02% sodium azide and 0.2% (v/v) Tween 20 and incubated with 
different primary antibodies overnight at 4oC. The membranes were then washed 
with PBS containing 0.2% (v/v) Tween 20 and incubated with corresponding 
secondary antibodies conjugated with HRP for 1 h at room temperature. After 
washing, these proteins were detected by a chemiluminescence method. 
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examined by trypan blue exclusion assay.  As expected, both U3A and LNcap 
cells were not responded to the IFN-γ/dsRNA treatment (Figure 2.4.11, Figure 
2.4.12, and Figure 2.4.13), suggesting that the Jak-stat signaling pathway is 
necessary for the IFN-γ/dsRNA-induced prostate cancer cell apoptosis. 
 
PKR is not involved in the IFN-γ/dsRNA induced PC3 cell apoptosis  
As mentioned previously, IFNs, in most cases, induce apoptosis through 
stimulating the expression of certain IFN-stimulated genes (ISGs). Here we 
checked the role of several ISGs in the IFN- γ/dsRNA-induced apoptosis. PKR is 
a proapoptotic protein. As shown in Figure 2.4.14 [Samuel, 2001], after being 
induced by IFNs, PKR is activated by dsRNA, commonly from viral infection 
(ssRNA forms some dsRNA segments in its secondary structure). The activated 
PKR phosphorylates the eukaryotic initiation factor 2α and subsequently inhibits 
mRNA translation. As a result, viral replication and cell proliferation are inhibited.  
Previous studies have demonstrated that PKR can mediate cell apoptosis in 
various cell types [Jagus, et al., 1999]. To test whether PKR is involved in IFN-
γ/dsRNA-induced PC3 cell apoptosis, the expression of PKR in PC3 cells was 
knocked down by PKR siRNA, and then the cells were treated with IFNs/dsRNA 
as previously described. The results showed that IFN-γ combined with dsRNA 
had similar effects on the PKR knockdown PC3 cells as on normal PC3 cells 
(Figure 2.4.15). The expressing level of PKR in PC3 cells is very low and PKR 
does not respond to IFN-γ induction either. To prove that PKR siRNA can knock 
down the expression of PKR effectively, the siRNA trasfected cells were treated 
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with 1000 unites/mL of IFN- and then western blot analysis was conducted to 
examine PKR protein expression. As shown in Figure 2.4.16, PKR siRNA 
effectively knocked down the expression of PKR in the cells. Thus, these results 
ruled out the involvement of PKR in IFN-γ/dsRNA-induced apoptosis in PC3 cells. 
 
RNase L is not involved in the IFN-γ/dsRNA induced PC3 cell apoptosis  
     RNase L is another dsRNA related ISG. It is one of the key enzymes for the 
IFN’s function against cell proliferation and viral infection. In this system, IFNs  
induce the expression of oligoadenylate synthetase (OAS), whose activity is 
regulated by dsRNA. OAS catalyzes the synthesis of oligoadenylates of the 
general structure pp(A2’p)n, commonly abbreviated as 2-5 A. As a latent 
endoribonuclease, RNase L is activated by the binding of 2-5A and leads to the 
degradation of viral and cellular RNA. As a result, viral replication is inhibited and 
cells undergo apoptosis (Figure 2.4.17) [Samuel, 2001]. To test whether RNase L 
contributes to IFN-γ/dsRNA induced PC3 cell apoptosis, the expression of 
RNase L in PC3 cells was knocked down by RNase L siRNA (Figure 2.4.18) and 
then the cells were treated as previously described. Our results showed that 
although the expression of RNase L was knocked down by RNase L siRNA, PC3 
cells were still sensitive to the treatment of IFN-γ/dsRNA (Figure 2.4.19). The 
expression of RNase L in PC3 cells treated with different IFNs and/or dsRNA 
was also examined by a western blot assay (Figure 2.4.20). These results 
showed that IFN-γ/dsRNA treatment did not induce a significant difference in the 
expression of RNase L. 
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Figure 2.4.11 Effect of IFN-γ/dsRNA on the viability of LNcap cells LNcap 
cells were treated with IFN-γ and/or dsRNA for 72 h and the viability of the 
treated cells was analyzed by a trypan blue exclusion assay.  
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Figure 2.4.12 Effect of IFN-γ/dsRNA on the viability of U3A cells U3A cells 
were treated with IFNs and/or dsRNA. The viability of the treated cells was 
analyzed by a trypan blue exclusion assay. 1, Control; 2, dsRNA alone; 3, IFN-α; 
4, IFN-; 5, IFN-γ; 6, IFN-α/dsRNA; 7, IFN-/dsRNA; 8. IFN-γ/dsRNA  
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Figure 2.4.13 Effect of IFN-γ/dsRNA on the viability of 2FTGH cells. 2FTGH 
cells were treated with IFNs and/or dsRNA. The viability of the treated cells was 
analyzed by a trypan blue exclusion assay.  1, Control; 2, dsRNA alone; 3, IFN-α; 
4, IFN-; 5, IFN-γ; 6, IFN-α/dsRNA; 7, IFN-/dsRNA; 8, IFN-γ/dsRNA 
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Figure 2.4.14 Role of PKR in IFNs’ functions [Samuel, 2001]  
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Figure 2.4.15 Role of PKR in IFNs/dsRNA-induced PC3 cell apoptosis PC3 
cells were transfected with PKR siRNA. At 30 h after transfection, the cells were 
treated with IFNs and/or dsRNA. The apoptotic cells were analyzed by a trypan 
blue assay. 1, Control; 2, dsRNA alone; 3, IFN-α; 4, IFN-; 5, IFN-γ; 6, IFN-
α/dsRNA; 7, IFN-/dsRNA; 8, IFN-γ/dsRNA 
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Figure 2.4.16 Knockdown of PKR by siRNA in PC3 cells  PC3 cells were 
transfected with PKR siRNA and then were treated with 1000 unites/mL of IFN-. 
The expression level of PKR in the cells was analyzed by a western blot analysis. 
1, Control; 2, IFN-α; 3, PKR siRNA; 4, PKR siRNA+IFN-α   
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Figure 2.4.17 The 2-5 A system [Samuel, 2001]  
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Figure 2.4.18 Knockdown of RNase L by siRNA in PC3 cells PC3 cells were 
transfected with RNase L siRNA using the Lipofectamine 2000 reagent. After 30 
h incubation, the cells were collected, lysed and a western blot analysis was 
performed to evaluate the protein expression of RNase L.  
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Figure 2.4.19 Role of RNase L in IFN-γ/dsRNA induced PC3 cell apoptosis 
The RNase L knockdown cells were treated with IFN-γ and/or dsRNA and the 
viability of the treated cells was analyzed by a trypan blue exclusion assay.  
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Figure 2.4.20 Expression of RNase L in IFNs/dsRNA treated PC3 cells A 
western blot analysis was conducted to evaluate the protein expression of RNase 
L in PC3 cells treated with IFNs and/or dsRNA.  
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INF-γ has no effect on the expression of death associate protein 3 (DAP3) 
and 5 (DAP5)  
     Death associated proteins (DAPs) are uniquely induced by IFN-γ, and the role 
of DAPs in mediating IFN-γ induced apoptosis in certain cell types has been well 
established in recent years [Kissil,et al., 1995; Hirota, et al., 2004]. To determine 
whether DAPs are responsible for IFN-γ/dsRNA-induced PC3 cell apoptosis, 
DAP3 and DAP5 were examined by Western blot analysis. The results showed 
that there was no difference in the expression of DAP3 and DAP5 between the 
control and IFN-γ treated PC3 cells (Figure 2.4.21). This suggests that DAP3 and 
DAP5 were not responsible for this event.  
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Figure 2.4.21 Expression of DAPs in IFN-γ treated PC3 cells PC3 cells were 
treated with 1000 unit/mL of IFN- and the expression of death associated 
proteins (DAPs) was analyzed by a western blot assay.   
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2.5 Discussion 
     In this study, we examined the effect of dsRNA and IFNs on the apoptosis of 
PC3 cells and discovered that pretreatment of human PC3 prostate cancer cells 
with IFNs, especially IFN-γ, significantly enhances the vulnerability of these cells 
to dsRNA-induced apoptosis. Similar results were obtained on DU145 cells which 
are another type of prostate cancer cell line, while other types of cancer cells 
displayed a dramatic difference in response to the stimulation with the subtypes 
of IFN.  
     RNase L and PKR are two IFN-inducible proteins which are very important in 
many IFN regulated events. Previous studies showed that increased expression 
of 2-5A syntheses was observed in both HeLa cells and mouse L-cells treated 
with IFN-β and dsRNA [Nilsen et al., 1981; Goswami and Sharma, 1984]. 
Furthermore, INF-γ is able to induce the expression of 2-5A synthetase in human 
colon carcinoma cell line BE, but there is no synergistic effect observed in the 
combination of IFN-γ and dsRNA [Chapekar and Glazer, 1986]. These results 
are consistent with our finding that RNase L-deficient PC3 cells are still sensitive 
to the treatment of IFN-γ and dsRNA.  In addition, there was no overt difference 
in the RNase L expression in the cells treated with or without the dsRNA/IFN-γ. 
All of these suggest that RNase L may not be involved IFN-γ/dsRNA-induced 
apoptosis in PC3 cells.  Magnusson et al. [2006] reported that arthritis triggered 
by dsRNA is not dependent on PKR. In the present study, after the expression of 
PKR was knocked down by siRNA, the PC3 cells were still sensitive to the 
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treatment of IFN-γ/dsRNA, suggesting again that PKR does not participate in the 
event. 
     The JAK/STAT pathway has been well established during the studies on the 
IFNs’ function. It has been observed that Stat1 is required for IFN-inducible 
responsiveness to the extracellular dsRNA [Elco and Sen, 2007]. Arthritis 
triggered by dsRNA is associated with the ability to produce type I IFN and is 
critically dependent on type I IFN receptor signaling [Magusson et al., 2006]. U3A 
cells, which lack STAT1, were not sensitive to IFN-γ/dsRNA. However, IFN-
γ/dsRNA are able to synergistically induce apoptosis in 2ftgh, the parental cells 
of U3A, implicating that the JAK/STAT pathway is necessary for this event. 
Furthermore, LNcap cells, which are deficient in Jak1, were resistant to the IFN-
γ/dsRNA treatment. Taken together, these data indicate the JAK/STAT pathway 
is indispensable for the apoptosis induced by IFN-γ/dsRNA in PC3 cells.  
     Either dsRNA or IFN- is able to induce a broad range of gene expressions 
[Potten and Wilson, 2004]. In the global profiling of dsRNA and IFN-γ-induced 
genes in rat pancreatic beta cells, one of the BCL-2 family members, Bax, is 
highly inducible [Rasschaert,  et al., 2003]. Noxa is another protein induced by 
the cells exposed to dsRNA, interferon, and virus [Sun and Leaman, 2005]. To 
determine whether any of the Bcl-2 family members is involved in PC3 cell 
apoptosis induced by IFN-γ/dsRNA, we examined the expression of several Bcl-2 
family proteins and found that Bak was upregulated by IFN-γ/dsRNA, implying 
that apoptosis in PC3 cells induced by IFN-γ/dsRNA depends on the participation 
of mitochondria. 
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CHAPTER III 
STUDIES ON THE BIOLOGICAL ROLES OF TRANSMEMBRANE AND COILED-
COIL DOMAINS 1  
 
 
3.1 Abstract 
     Transmembrane and coiled-coil domains 1 (TMCO1) is a membrane-
associated protein and belongs to the DUF841 superfamily of several eukaryotic 
proteins with unknown functions. The human TMCO1 gene is located on 
chromosome 1q22-q25.  A homozygous frame shift mutation in the TMCO1 gene, 
c.139_140delAG, has been identified in patients with TMCO1 defect syndrome 
(TDS). TDS is characterized by distinctive craniofacial dysmorphism, skeletal 
anomalies, and mental retardation. To further investigate the biological functions 
of TMCO1, we first attempted to generate an antibody against TMCO1 protein. In 
this study, human TMCO1 was expressed in both bacteria and mammalian cells. 
The recombinant TMCO1 expressed in bacteria was purified in preparation for a 
workable antibody. Subcellular localization using the immune-fluorescent staining 
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technique revealed that TMCO1 may be mainly expressed in the mitochondria of 
cells. Interestingly, the lymphocytes isolated from the peripheral blood of the 
patients with TDS grew significantly faster than those from healthy individuals, 
suggesting that TMCO1 may be involved in the regulation of cell proliferation.  In 
addition, we have generated a TMCO1 knockdown cell line, which can be used 
for further the study of the molecular basis underlying TDS. 
 
3.2 Introduction 
     TMCO1 is a plasma membrane-associated protein located in the long arm of 
the 1st chromosome. Recently, it was found that the homozygous mutation in 
TMCO1 caused a syndrome with craniofacial dysmorphism, skeletal anomalies 
and mental retardation, named TMCO1 defect syndrome (TDS) [Xin, et al., 2010]. 
TDS is an autosomal recessive condition in Old Order Amish of Northeastern 
Ohio, and a homozygous 2-base pair deletion within exon 2 of the TMCO1 gene 
was identified. Though the function of this gene is still unclear, distribution 
analyses revealed that TMCO1 is universally expressed in all human tissues and 
is highly conserved among multiple species.  The ubiquitous expression pattern 
in human adult and fetal tissues and the high sequence conservation may 
suggest that TMCO1 plays important biological roles. Structural analysis 
indicates that the TMCO1 gene consists of one coiled-coil domain and two 
transmembrane domains, and there are 3 phosphoserine residues identified, 
which may participate in signaling transduction. Currently, the study concerning 
the function of TMCO1 is largely lacking, although some reports show that the 
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TMCO1 gene is regulated by different events--for instance, fast, cancer, and 
diabetes. [Lkhagvadorj, et al., 2009; Kondrakhin, et al. 2008; Dokmanovic-
Chouinard et al., 2008; Yu, et al., 2009]. In this study, we subcloned the TMCO1 
gene into several mammalian cell expression vectors and an ectopic expression 
of the gene in different cell types. By using these cell lines we determined the 
localization of TMCO1 and examined the effect of TMCO1 on cell functions. We 
also generated an effective antibody against human TMCO1. Based on the 
results obtained from lymphocyte cells derived from TDS patients and TMCO1 
knockdown cell lines, TMCO1 may play an important role in cell proliferation. 
 
3.3 Materials and methods 
 
Materials and reagents 
     Human TMCO1 cDNA was purchased from ATCC (Manassas, VA). pET-21d 
vector was from Novagen (Brookfield, WI). pIREShyg vector was purchased from 
Clontech (Brookfield, WI ). Choice-Taq™ DNA Polymerase was from Denville 
Scientific INC. (Metuchen, NJ). All digestion enzymes and the T4 DNA ligase kit 
were obtained from New England Biolab (Ipswich, MA). The QIAEXii gel 
extraction and QIAprep Spin Miniprep kits were purchase from Qiagen (Valencia, 
CA). SOC medium and ultrapure agarose were from Invitrogen (Carlsbad, CA). 
XL10-gold ultrocompetent cell was from Stratagen (Kirkland, WA).   
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Subcloning of TMCO1 to pET-21d               
     To express TMCO1 in E. coli, TMCO1 cDNA was subcloned to pET-21d 
vector with a His-tag (Figure 3.3.1).  The TMCO1 cDNA was amplified by 
polymerase chain reaction (PCR)  from pOTB7 vector in a reaction mixture (50 
μL) containing 10 mM Tris-HCl (pH 8.3), 10 mM KCl, 1.5 mM MgCl2, 8mM 
(NH4)2SO4, 0.05% NP-40, 200 mM each deoxynucleoside triphosphate, 1.0 U of 
Taq polymerase, and 0.5 μg of a pair of primers. The first denature step was 
done at 94°C for 3 min. The PCR amplification was carried out for 30 cycles 
consisting of template denaturation (1 min at 94°C), primer annealing (45 sec at 
55°C), and polymerization (1 min at 72°C). The final extension step was 1 cycle 
of 72oC for 8 min.  The forward primer used was 5’GGT GCG ACC ATG GGC 
ACT ATG TT3’ and the reverse primer was 5’AGA ACT CCT CGA GAG AGA 
ACT TCC3’. Both PCR products and pET-21d vector were digested with 
restriction enzymes XhoI and NcoI. The digestion reaction mixture (50 μL) 
included 5 μL of PCR product or pET-21d vector DNA, 5 μL of buffer 2 and 3 μL 
of XhoI and ddH2O. The mixture was incubated at 37
0C for 1 h followed by 
adding additional 3 μL of NCOI and 2 μL of NaCl (0.1 M) then incubated for 
another 1 h. Both the PCR product digestion mixture and pET-21d vector 
digested mixture were separated by 1% agarose gel and undergone gel 
purification using the QIAEXii gel extraction kit. A T4 DNA ligase kit was used to 
ligate the DNAs. The ligation buffer contained 5 μL of pET-21d digestion mixture, 
4 μL of PCR product digestion mixture, 2 μL of 10X T4 buffer, 1 μL of T4 ligase, 
and distilled-deionized water (ddH2O) to 20 μL in total. The ligation reaction was 
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done at room temperature for 2 h, followed by transformation. Briefly, the mixture 
of 10 μL of ligation solution and 50 μL of XL10-gold ultracompetent cell (good for 
big size cloning) was left on ice for 30 min, 400C water bath for 90 sec, and ice 
for 2 min. Then 300 μL of SOC medium was added to the mixture and the tube 
was shaken at 370C for 1 h. Three hundred μL of the mixture was applied to a LB 
agarose plate with ampcillin (100 μg/mL) and incubated overnight at 37 0C. In the 
next morning, 12 single clones were picked up and grown in LB medium. 
TMCO1/pET-21d plasmid DNA was extracted using the QIAprep Spin Miniprep 
kit and trasformed to E. coli BL21 (DE3) competent cells (Sigma, St. Louis, MO) 
for protein expression. The authenticity of the clones was confirmed by DNA 
sequencing. 
 
Subcloning of TMCO1 to pIREShyg  
In order to express the TMCO1 gene in mammalian cells, TMCO1 cDNA was 
cloned to a pIREShyg vector. TMCO1 was amplified by PCR from the plasmid 
pOTB7 as previously described. The primers used for this PCR were 5’ CTA 
CGG ATC CCG TTT TCG CTT C3’ (forward) and 5’ GGC TCT GGA TCC AAA 
ACA GTT G3 (reverse). Both PCR product and pIREShyg vector (Figure 3.3.2) 
were digested with BamH1. After digestion, the DNAs were treated with alkaline 
phosphatase calf intestine (CIP) at 37oC for 30 min, followed by gel purification. 
The purified DNAs were ligated, and then transformed as described above. 
Purified TMCO1/ pIREShyg plasmid DNA was kept for the transfection. 
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Other subclonings 
     Several other constructs were generated. (1) TMCO1-pFLAG-CMV-2 (Figure 
3.3.3): primers used were 5’CGG CCG CGA ATT CGA GCA CTA TGT TC3’ 
(forward) and 5’GGC TAC CTA TGG CTC TTG CT3’ (reverse). EcoR1 and XbaI 
were used to digest the DNAs. (2) TMCO1-pCMV-Myc (Figure 3.3.4): the primers 
were the same as used for cloning TMCO1 to pFLAG-CMV-2, but restriction 
enzymes were EcoR1 and XhoI. (3) TMCO1-pCMV-HA (Figure 3.3.5): the 
primers were 5’AGG TGC GAA TTC AGA CTA TGT TCG C3’ (forward) and 
5’GAA AGA GGC TCG AGT AGT AAG GCT A3’ (reverse). EcoR1 and XhoI were 
used to digest the DNAs.   
 
Immunofluorescence staining 
     Human U87 cells were human glioblastoma-astrocytoma cells (ATCC, 
Manassas, VA). Cells were grown in RPMI-1640 medium (Media Lab of the 
Central Cell Service, Cleveland Clinic, Cleveland, OH) supplemented with 
streptomycin (100 µg/mL), penicillin (100 unites/mL)  and 10% cosmic calf serum 
(Hyclone, Logan, UT) in a humidified atmosphere of 5% CO2 at 37 
oC. U87Cells 
were seeded on BD FalconTM CultureSlides (BD Biosciences, Bedford, MA) and 
transfected with the pFlag-CMV-2 vector or pFlag-CMV-2/TMCO1 plasmid DNA 
using lipofectomine 2000 reagents (Invitrogen, Carlsbad, CA). After 30 h, 
transfected cells were incubated with growth medium containing 0.5 µM 
MitoTracker Red CMXRos (Invitrogen, Carlsbad, CA) for 15 min at 37oC and 
immunofluorescence was performed following standard protocols. In brief, after 
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Figure 3.3.1 pET-21d vector map (Novagen, Brookfield, WI) 
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Figure 3.3.2 pEREShyg vector information (Clontech, Brookfield, WI) 
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Figure 3.3.3 pFLAG-CMV-2 vector information (Eastman Kodak Company, 
New Haven, CT) 
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Figure 3.3.4 pCMV-Myc vector information (BD Biosciences, Palo Alto, CA) 
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Figure 3.3.5 pCMV-HA vector map and MCS (BD Biosciences, Palo Alto, CA) 
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 being rinsed with 1XPBS (Media Lab of the Central Cell Service, Cleveland 
Clinic, Cleveland, OH), the cells were fixed with 3% formaldehyde (Sigma, St. 
Louis, MO) for 15 min at room temperature, followed by 3 times of washing with 
PBS. The cells were then permeabilized with ice-cold methanol (Pharmco-
AAPER, Shelbyville, KY) for 10 min at -200C and blocked with block buffer (2.5 
mL of 10XPBS, 1.25 mL of normal goat serum, 75 μL of Triton X-100 and dH2O 
to 25 mL) for 60 min at room temperature, followed by incubation in primary 
antibody, a mouse monoclonal anti-Flag M5 antibody (Sigma-Aldrich, St. Louis, 
MO) overnight at 40C. Then the cells were rinsed with 1XPBS for 3 times and 
incubated with the secondary antibody: Dylight TM 488 conjugated Anti-mouse 
IgG (Cell signaling, Boston, MA), for 1.5 h at room temperature in dark. After 5 
times of washing with high salt PBS (0.4 M NaCl, 1XPBS), the walls of culture 
slides were removed, and the nuclei were counterstained with DAPI (Invitrogen, 
Carlsbad, CA). Then the slides were mounted with Prolong Gold Antifade 
Reagent (Invitrogen, Carlsbad, CA) and the edges of cover slips were sealed 
with nail polish. The slides were examined using a Delta Vision RT microscope. 
 
TMCO1 protein expression in E. coli BL21 cells 
     E.coli BL21 cells bearing TMCO1/pET-21d construct were grown in LB 
medium supplemented with ampicillin (100 μg/mL) to an O.D. value of 0.5 at 600 
nm and the expression of TMCO1 was induced by adding isopropyl 
thiogalactoside (IPTG) to a final concentration of 1 mM.  After being shaken at 
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30oC for 6 h, bacterial cells were harvested by centrifugation (1750 Xg at 40C for 
30 min). The cell pellets were frozen at -800C. 
 
Purification of TMCO1  
     The cell pellets were thawed and resuspended in lysis buffer (50 mM 
phosphate buffer with 800 mM NaCl, pH 8.0, 0.1% Triton X-100) on ice, followed 
by sonication  and centrifugation to sediment cell debris. The supernatant was 
diluted with 6 M guanidine HCl in 1:1 volume ratio to a final concentration of 25 
mM phosphate, 400 mM NaCl and 3 M guanidine HCl (pH 8.0). Then the diluted 
supernatant was mixed with a nickel-chelating histidine-binding resin (Qiagen, 
Valencia, CA) for 1 h and loaded into an empty column. After washed with PBS 
buffer containing 20 mM immidazole and 3 M guanidine HCl, the TMCO1 protein 
was eluted with PBS buffer containing 100 mM immidazole and 3 M guanidine 
HCl (pH 8.0). Fractions containing TMCO1 were pooled and dialyzed against 4 L 
Tris-buffered saline (1 mM EDTA, 1 mM benzamidine and pH 7.4) at 40C. The 
dialyzed sample was stored at -800C until use. 
 
Production of polyclonal anti-TMCO1 antibody 
     The amino acid sequence of TMCO1 was “MSTMFADTLLIVFISVCTALLAEG 
ITWVLVYRTDKYKRLKAEVEKQSKKLEKKKETITESAGRQQKKKIERQEEKLKN
NNRDLSMVRMKSMFAIGFCFTALMGMFNSIFDGRVVAKLPFTPLSYIQGLSHRN
LLGDDTTDCSFIFLYILCTMSIRQNIQKILGLAPSRAATKQAGGFLGPPPPSGKFS
,” which was submitted to GenSript Company (Piscataway, NJ) together with Hek 
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293 cell lysate as a positive control for pepetide polyclonal anti-TMCO1 antibody 
production. The antigen peptide designed and synthesized by GeneScript 
company was “CKIERQEEKLKNNNR.”  To gain an effective immunization effect, 
the peptide was conjugated with a big molecule Keyhole limpet hemocyanin 
(KLH).  Then the conjugated peptide antigen was used to immunize 6 rabbits. 
Affinity purification was used to purify the TMCO1 antibody from the serum of 
immunized rabbits.  
 
RNA isolation and RT-PCR 
     The lymphocytes from normal, carrier (one copy of TMCO1 gene was 
mutated), and affected (both copies of TMCO1 gene were mutated) individuals 
were pelleted in 15 mL centrifuge tubes and washed with PBS twice. The total 
RNA was isolated using Trizol (Invitrogen, Carlsbad, CA) according to the 
manufacturer’s instructions. Briefly, 3 mL of Trizol reagent was added to the tube. 
After a brief vortex, 0.8 mL of chloroform was added followed by vigorous vortex 
for 1 min. Samples were centrifuged at 10,000 x g for 30 min at 4oC and the 
colorless upper aqueous phase was moved to a new 15 mL centrifuge tube. After 
added equal amount of isopropyl alcohol and inverted for several times, the 
sample sat at room temperature for 10 min followed by centrifugation at 10,000 x 
g for 20 min at 4oC. Then the RNA precipitate formed a gel-like pellet on the side 
and bottom of the tube. The supernatant was discarded and 1mL of 80% ethanol 
(pre-cooled at –20oC) was used to suspend RNA. The RNA suspension was 
transferred to a new 1.5 mL microcentrifuge tube and centrifuged at 7,000 x g for 
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5 min at 4oC. Then the alcohol was removed as much as possible and the RNA 
was dissolved in 100 µL of diethyl pyrocarbonate (DEPC) (Sigma-Aldrich, St. 
Louis, MO)-treated RNase-free H2O by passing several times through a pipette 
tip. 
     One-step RT-PCR was performed using a SuperScriptTM One-Step RT-PCR 
with Platinum Taq Kit (Invitrogen, Carlsbad, CA) according to the manufacturer's 
instructions. First strand cDNA synthesis and pre-denaturation steps were done 
at 45oC for 30 min and 94oC for 2 min and were followed immediately by PCR 
amplification. PCR amplification conditions were as follows: 35 cycles of 
denaturation at 94oC for 1 min, annealing at 55oC for 45 sec, and extension at 
72oC for 1 min 30 sec. Finally, 1 cycle of final extension was set at 72oC for 8 min.  
 
Western blot analysis     
     Lymphocytes were harvested from normal, carrier, or affected individuals.  
Cytoplasmic extracts were prepared by suspension of cell pellets in NP-40 lysis 
buffer. After centrifugation in a microcentrifuge at 40C for 10 min, the supernatant 
was removed. Cellular extracts were fractionated on SDS-12% polyacrylamide 
gels and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, 
MA). The membranes were blocked with 5% non-fat milk in PBS containing 
0.02% sodium azide and 0.2% (v/v) Tween 20 and incubated with TMCO1 
antibody (Genescript, NJ) overnight at 4oC. The membranes were then washed 
with PBS containing 0.2% (v/v) Tween 20 and incubated with anti-rabbit IgG 
secondary antibody conjugated with HRP (Cell Signaling Technology, Boston, 
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MA) for 1 h at room temperature. After the washing step, these proteins were 
detected by a chemiluminescence method, according to the manufacturer’s 
specification (Amersham, Piscataway, NJ). The expression of TMCO1 in different 
cell lines was examined.  
 
Knockdown of TMCO1’s expression 
     Oligonucleotides coding for short hairpin RNA (shRNA) specifically against 
TMCO1 were cloned into pSilence 4.1-CMV neo (Ambion, Austin, TX). The 
following target regions of TMCO1 were chosen: (1) GCCAUAGGUAGCCUUACUA; 
(2) GCAAGUUGGCUGUCUAUGA and (3) CAAGGAGAGAUCUGUUUCA. 
Stably transfected clones were established by selection with G418 (Calbiochem, 
Brookfield, WI). The TMCO1 expression in each picked clone was examined by 
western blot assay. 
 
Growth rate of lymphocytes from patients with TMCO1 defect 
     To check the effect of TMCO1 on the growth of lymphocytes, 6.27X10^5 of 
lymphocytes from normal, carried, or affected individuals were seeded to each 
flask respectively. Cells were counted using trypan blue dye exclusion assay 
after 6 days and the medium color of each flask was recorded. 
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3.4 Results 
 
TMCO1 was subcloned to the pET-21d and pIREShyg vectors 
     In order to explore the function of TMCO1, we attempted to prepare an anti-
TMCO1 antibody by using a purified recombinant TMCO1 protein. TMCO1 cDNA 
was subcloned into the pET-21d vector, which was fused with a His tag, using 
XhoI and NCOI.  Several clones were identified as the right clones and the 
constructs were further confirmed by DNA sequencing (Figure 3.4.1 and Figure 
3.4.2). In addition, TMCO1 was inserted into pIREShyg using Bam H1 and the 
constructs were confirmed by DNA sequencing as well (see Figure 3.4.3). 
 
Purification of the recombinant TMCO1 protein  
     The purification of recombinant TMCO1 was achieved by using metal 
chelation affinity chromatography.  As shown in Figure 3.4.4, after induction, the 
expressed TMCO1 protein in the cell lysate was passed through an affinity 
column packed with Ni2+ saturated beads and the bound recombinant TMCO1 
protein was eluted with 100 mM immidazole after the column was washed with 
20 mM immidazole. The insolubility of a recombinant protein expressed in 
bacteria is a common problem. To increase the yield, 6 mM guanidine 
hydrochloride (GnCl) was added to the cell lysate to promote the solubility of the 
recombinant TMCO1 protein during the purification process.  After purification, 
GnCl was removed by dialysis. The purified protein was analyzed by SDS-PAGE 
(Figure 3.4.5). However, although the purity of the purified recombinant TMCO1  
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Figure 3.4.1 Digestion of PCR products and vectors TMCO1 cDNA was 
amplified by PCR and both PCR products and vectors were digested with 
corresponding restriction enzymes.  
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Figure 3.4.2 TMCO1/pET-21d clone selection After subcloing, 12 clones were 
picked up and cultured in LB medium. Plasmid DNA was purified from each clone 
and digested by XhoI and NCOI.  
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Figure 3.4.3 TMCO1/pIREShyg clone selection After subcloing, 12 clones were 
picked up and cultured in LB medium. Plasmid DNA was purified from each clone 
and digested by XbaI.  
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Figure 3.4.4 Purification of TMCO1 protein by nickel affinity 
chromatography E.coli BL21 cells bearing TMCO1/pET21-d construct were 
grown in LB medium supplemented with ampicillin (100 μg/mL) to an OD value of 
0.5 at 600 nm and the expression of TMCO1 as induced by adding IPTG to a 
final concentration of 1mM. After being shaken at 30oC for 6 h, bacteria cells 
were pelleted, lysed, and mixed with nickel charged beads. The impurities were 
washed away by 20 mM imidazole and most TMCO1 protein was eluted by 100 
mM  imidazole. The collection from each step was separated by SDS-PAGE and 
stained by Coomassie brilliant blue.  
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Figure 3.4.5 Purified TMCO1 protein 
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protein was very good, it was difficult to prepare a sufficient amount of protein to 
immunize an animal.  Thus, we lately made an anti-TMCO1 antibody by using 
synthesized peptides. 
 
Localization of TMCO1  
     To determine the subcellular localization of TMCO1, U87 cells were 
transfected with either TMCO1- pFLAG-CMV-2 or TMCO1- pCMV-HA. After 48 h, 
the cells were labeled with antibodies against FLAG or HA, respectively, and 
then stained with Dylight TM 488 conjugated Anti-mouse IgG. As shown in Figure 
3.4.6, TMCO1 was localized in mitochondria of U87 cells. However, the result 
needs to be further confirmed. 
 
TMCO1 mRNA, but not the protein, is expressed in the lymphocytes of 
patients with TMCO1 defect syndrome 
     To investigate the expression of TMCO1 at the transcriptional level in the 
lymphocytes of patients with TDS, the total RNA was extracted from the cells 
isolated from normal, carrier and affected individuals, and the mRNA expression 
levels of TMCO1 were examined by RT-PCR (Figure 3.4.7). GAPDH was 
examined as a control.  Apparently, there was no significant difference at the 
level of TMCO1 mRNA between the normal individuals and patients with TDS. To 
determine the expression of TMCO1 at its protein level, cell lysate obtained from 
the cells of normal and carrier individuals as well as patients with TDS, were 
subjected to a western blot analysis. As expected, there was not a full length of  
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Figure 3.4.7 TMCO1 mRNA expression in human lymphocytes The total RNA 
of the lymphocytes from normal, carrier, and affected individuals was isolated 
using the Trizol reagent and the mRNA expression was evaluated by One-step RT-
PCR.  
 
 
 
 
 
 
 
108 
 
 
 
 
 
 
 
TMCO1
Actin
 
 
Figure 3.4.8 TMCO1 protein expression in human lymphocytes Cell extracts 
of lymphocytes from normal, carrier and affected individuals were separated by 
12% SDS-PAGE. A western blot assay was conducted using an anti-TMCO1 
primary antibody. 
 
 
 
 
 
109 
 
TMCO1 protein detected in the cell extract from patients with TDS, which 
supports the conclusion drawn previously based on the observation of the 
patients’ phenotypes (Figure 3.4.8). 
 
TMCO1 is ubiquitously expressed in all cells examined 
     In order to examine the differential distributions of TMCO1 in human cells, the 
relative protein expression levels of TMCO1 were evaluated by a western blot 
analysis in prostate cancer cell lines (PC3 and LNcap), brain cancer cell 
line(U87), ovarian cancer cell line (Hey1B), liver cancer cell lines (HEPG2, 
HEP3B, A549, H292 and H522), neuroblastoma cell line (N1E115), fibrosarcoma 
cell line (HT1080), and embryonic kidney cell line (Hek 293). Although TMCO1 is 
ubiquitously expressed in all cells examined, its expression was relatively higher 
in PC3 cells, LNcap cells, Hey 1B cells, HEOG2 cells, HEP3B cells and H522 
cells (Figure 3.4.9). 
 
TMCO1 is knocked down by TMCO1 shRNA in U87 cells 
     To investigate the biological role of TMCO1, we knocked down TMCO1 in 
U87 cells. The cells were transfected with TMCO1 shRNA pSilence4.1-CMVneo, 
and selected in medium containing 400 ug/mL of G418. Four groups of 
constructs, one scrambled shRNA and three different TMCO1 shRNAs, were 
used to transfect the cells. Twelve clones from each group were examined by 
western blot analysis using a polyclonal antibody to human TMCO1. As shown in 
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Figure 3.4.10 and Figure 3.4.11, the expression of TMCO1 was significantly 
knocked down in the clones: B2, B5, and C7.     
 
TMCO1 may be involved in the regulation of cell proliferation 
     Since one of the phenotypes in patients with TDS was abnormally growing, 
we determined the effect of TMCO1 on cell proliferation.  Interestingly, we found 
that the lymphocytes from the affected patients grew much faster than the cells 
from normal and carried individuals (Figure 3.4.11). The doubling time of the 
lymphocytes from the patients was 36 h, whereas the cells from the healthy 
individuals needed 48 h to reach the cell numbers. This observation was 
confirmed by the medium color in the cell seeded with the same number of 
lymphocytes. Overtly, lymphocytes from the patients consumed nutrients much 
faster (Figure 3.4.12). Furthermore, TMCO1 knocked down cells such as B2, B5 
and C7 also grew 1.5-fold faster than control cells. These results suggest that 
TMCO1 may play an important role in cell proliferation. 
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Figure 3.4.9 TMCO1 expression in different cell lines Cell extracts were 
obtained from different cell lines as indicated and the expression of TMCO1 
protein was determined by a western blot analysis using anti-TMCO1 antibody. 
112 
 
 
 
 
 
 
A7     A8     B3     C3     C7 C10   D5     D9   D10
A12   A10  B2 B4   B7  B8  C2   C4   C9   D2   D12   
A6      B5 B6     C1     C5   C12    D3   D4    D11   
A4       B1      B9        C6       C11      D1      D7  
 
 
Figure 3.4.10 TMCO1 knockdown clone selection U87 cells were stably 
trasfected with TMCO1 shRNA construct using lipofectomine 2000 and the 
clones were selected by 400 µg/mL of G418. The expression of TMCO1 in the 
selected clones was determined by a western blot analysis using an anti-TMCO1 
antibody. A, mock (control); B, C and D, TMCO1 shRNA 
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Figure 3.4.11 TMCO1 is knocked down by TMCO1 shRNA 
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Figure 3.4.12 Effect of TMCO1 on the growth of human lymphocytes 
Lymphocytes from normal, carrier, and affected individuals were seeded at 
6.27X105 cells in each flask and the cells were counted by a trypan blue dye 
exclusion assays after 6 days. 
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Figure 3.4.13 Medium color changes related to the growth of human 
lymphocytes Lymphocytes from normal, carrier, and affected individuals were 
seeded at 6.27X105 cells in each flask and the medium color in the flasks was 
recorded on day 6. Carrier: R-6287, R-6289 and R-6301A; Affected: R-6288 and 
R-6300A 
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3.5 Discussion 
     TMCO1 is a transmembrane protein with one coiled coil domain. The coiled 
coil is a structural motif in proteins in which 2-7 alpha-helices are coiled together 
like the strands of a rope. It has been found that approximately 10% of all protein 
sequences have coiled coil motifs which are extremely stable and responsible for 
the oligomerization of proteins in a highly specific manner [McFarlane, et al., 
2009].   The functions of coiled coil type proteins are diverse and are involved in 
different important biological processes including cytokinesis (Lee, et al., 2008), 
gene transcription (Landschulz, et al., 1988) and regulation (Nooren, et al., 1999), 
membrane fusion (Deng, et al., 2006), molecular motors (Yun, et al., 2003), 
muscle fibres (Strelkov, et al.,2002), apoptotic cleavage site (Lin, et al.,2007), 
multidrug resistance (Higgins, et al., 2004), and the potential delivery systems 
either in the development of novel vaccines (Schroeder, et al.,2009) or for the 
treatment of cancer (Erikssonet, et al., 2009). The universal expression of 
TMCO1 in all tissues examined [Xin, et al., 2010; Zhang, et al., 2010; Iwamuro, 
et al., 1999] and the highly evolutionary conservation in large animals implicate a 
critical role of TMCO1. Our result showed that TMCO1 may be located in the 
mitochondria of U87 cells, which is consistent with previous findings that TMCO1 
is located in the mitochondria of PK-15 cells (pig kidney cells). As an energy 
plant in the body, one of the main mitochondrial functions is to produce cellular 
ATP which is essential for eukaryotic cells. There are many nuclear encoded 
proteins which are imported into the intermembrane space of mitochondria where 
they adopt a coiled coil fold and can perform either oxidoreductase or 
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metallochaperon function [Banci, et al., 2009]. These characteristics of TMCO1 
may give a hint about its biological function in cells.     
     TDS is a unique autosomal recessive condition with significant clinical 
phenotypes including generalized dimorphism disorders with craniofacial, 
skeletal, and CNS features such as brachycephaly and mental retardation. The 
molecular mechanism by which TMCO1 defect causes these clinical features is 
of great interest. One striking characteristic in several TSD patients is tall stature 
[Xin, et al., 2010]. It is possible that TMCO1 controls the elongation of the bones 
and dysmorphic proportion [Scotos and Argente, 2008]. Tall stature can be seen 
in several other syndromes. For instance, estrogen, as a factor to arrest growth, 
is deficient in aromatas deficiency, estrogen receptor deficiency, and 
hypogonadism which result in the tall stature. FBN1, TGFBR2, FBN2, and 
cystathionine -synthase are essential for inhibiting elongation of the bones and 
dysmorphic proportion,  the defect of these genes leads to Marfan syndrome I, 
Marfan syndrome II, Beads syndrome, and homocystinuria type 1 respectively 
[Argente, et al., 2000]. Our results showed that the lymphocytes from patients 
with TDS grew significantly faster than that from normal individuals, suggesting 
that TMCO1 may be involved in cell proliferation, cell cycle, cell growth, and 
tumor suppression. Further investigation needs to be done to elucidate how 
TMCO1 contributes to the cell proliferation. 
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